These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6802504)

  • 1. Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.
    Lau CY; Wang EY; Goldstein G
    Cell Immunol; 1982 Jan; 66(2):217-32. PubMed ID: 6802504
    [No Abstract]   [Full Text] [Related]  

  • 2. The immunomodulating effect of TP5 and indomethacin in burn-induced hypoimmunity.
    Maghsudi M; Miller CL
    J Surg Res; 1984 Aug; 37(2):133-8. PubMed ID: 6235402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Model for acquired immunodeficiency caused by anesthesia and surgical procedures. Effect of treatment with thymopoietin pentapeptide (TP5)].
    Auteri A; D'Aniello C; Falotico N; Saletti M; Di Perri T
    Recenti Prog Med; 1986 Sep; 77(9):423-8. PubMed ID: 3541085
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
    Levinsky RJ; Davies EG; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic use of TP5 (thymopoietin 32-36) in sarcoidosis of the skin.
    Thivolet J; Faure M; Nicolas JF; Mauduit G; Claudy A
    Clin Immunol Immunopathol; 1983 Mar; 26(3):350-60. PubMed ID: 6347481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of TP-3 (Arg-Lys-Asp), TP-4 (Arg-Lys-Asp-Val), and TP-5 on the metastatic capacity of intravenously injected Lewis lung tumor cells.
    Szende B; Lapis K; Pal K; Sipos L; Denes L; Kisfaludy L
    Immunopharmacol Immunotoxicol; 1987; 9(1):19-24. PubMed ID: 3330095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
    Williams RC; Montano JD; Bankhurst AD
    J Lab Clin Med; 1983 Jan; 101(1):152-60. PubMed ID: 6217268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide].
    Djawari D; Bolla K; Haneke E
    Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymopentin in experimental and clinical medicine.
    Surv Immunol Res; 1985; 4 Suppl 1():1-156. PubMed ID: 3898279
    [No Abstract]   [Full Text] [Related]  

  • 11. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients.
    Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J
    Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382
    [No Abstract]   [Full Text] [Related]  

  • 12. [Correction of lipid peroxidation in stress with the peptide bioregulator thymopentin].
    Deviatkina TA; Brechko VV; Tarasenko LM; Zviago'lskaia IN; Bezuglyĭ IuV; Rituma IR; Klusha VE
    Fiziol Zh (1978); 1989; 35(5):14-8. PubMed ID: 2687033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and tolerability of thymopoietin in patients at risk of infection].
    Recenti Prog Med; 1987; 78(7-8):358-64. PubMed ID: 3321257
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunostimulation by TP-5 in immunocompromised patients and animals--current status of investigation.
    Waymack JP; Alexander JW
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):225-32. PubMed ID: 3539496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thymopentin treatment of ovarian carcinoma: preliminary clinical results].
    Garozzo G; Granà G; Lomeo E; La Greca M; Castiglione MG; Caruso M; Curatolo M; Gurgone P
    G Ital Oncol; 1988; 8(1):11-3. PubMed ID: 3065223
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic possibilities of thymopoietin fragments (TP3 and TP4) based on experimental animal models.
    Dénes L; Szende B; Hajós G; Szporny L; Lapis K
    Drugs Exp Clin Res; 1987; 13(5):279-87. PubMed ID: 3500029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of recurrent oral aphthae with thymopoetin pentapeptide].
    Djawari D; Haneke E
    Hautarzt; 1983 Sep; 34(9):463-4. PubMed ID: 6355012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of thymopentin on the anaemia of chronic lymphoproliferative disorders.
    Paladini G; Tosato F
    Haematologica; 1986; 71(6):519-20. PubMed ID: 3104165
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of thymopentin on the anaemia of myelodysplastic syndromes. A preliminary study.
    Catarini M; Sebastianelli G; Romagnoli R; Leoni P
    Recenti Prog Med; 1989 Jan; 80(1):46. PubMed ID: 2652223
    [No Abstract]   [Full Text] [Related]  

  • 20. Thymopentin in dermatology.
    Haneke E
    Curr Probl Dermatol; 1989; 18():283-9. PubMed ID: 2663371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.